Iohexol Adoh (Iohexol)

Iohexol contains multiple iodine atoms that absorb X‑rays more effectively than surrounding tissues. When injected intra‑arterially or intravenously, the iodine creates a temporary increase in radiodensity, highlighting vascular and extracellular spaces on X‑ray‑based imaging modalities.

The dose of Iohexol Adoh is individualized and determined by the prescribing physician based on the specific imaging study, patient weight, renal function, and the required level of contrast enhancement. No standard dose is provided here.

Iohexol Adoh is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are no adequate human studies. It should be used in pregnancy only if the diagnostic benefit outweighs potential risks. Limited data are available for breastfeeding; clinicians should weigh benefits against possible exposure to the infant.

To order Iohexol Adoh, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials. The sales team will then respond with pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Iohexol is a non‑ionic, low‑osmolality iodinated contrast medium, offering a favorable safety profile compared with older high‑osmolality agents. Compared with alternatives such as iopamidol or iopromide, Iohexol provides similar image quality while generally causing fewer adverse reactions, though individual patient tolerance can vary.

Iohexol Adoh should be stored at ambient temperature, typically below 25 °C, in its original sealed container. Protect the product from direct sunlight, excessive heat, and moisture. Do not freeze the solution, and inspect the vial for particulate matter before use.

Iohexol Adoh is administered by a qualified healthcare professional via intra‑arterial or intravenous injection, usually through a peripheral or central venous line. The injection rate and volume are tailored to the imaging protocol and patient characteristics, and the procedure is performed under sterile conditions.

The most serious risks include severe allergic reactions (anaphylaxis), acute kidney injury, hypotension or cardiovascular collapse, and rare neurologic events such as seizures. Patients with pre‑existing renal impairment, known iodine allergy, or uncontrolled thyroid disease require careful assessment before use.

Iohexol Adoh is contraindicated in patients with a documented hypersensitivity to iodinated contrast media or any of its components. Caution is advised for individuals with severe renal insufficiency, uncontrolled hyperthyroidism, or a history of severe allergic reactions. Pregnant women should only receive it when the diagnostic benefit justifies potential risk.